Neoadjuvant therapy for pancreatic cancer
Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …
surgical resection of the primary tumour and systemic chemotherapy, which provides …
Guidelines for perioperative care for pancreatoduodenectomy: enhanced recovery after surgery (ERAS) recommendations 2019
Background Enhanced recovery after surgery (ERAS) pathways are now implemented
worldwide with strong evidence that adhesion to such protocol reduces medical …
worldwide with strong evidence that adhesion to such protocol reduces medical …
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients, yet harbours
mutation-derived T cell neoantigens that are suitable for vaccines,. Here in a phase I trial of …
mutation-derived T cell neoantigens that are suitable for vaccines,. Here in a phase I trial of …
Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial
T Conroy, F Castan, A Lopez, A Turpin… - JAMA …, 2022 - jamanetwork.com
Importance Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group
PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified …
PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified …
Optimizing the outcomes of pancreatic cancer surgery
O Strobel, J Neoptolemos, D Jaeger… - Nature reviews Clinical …, 2019 - nature.com
Pancreatic cancer is likely to become the second most frequent cause of cancer-associated
mortality within the next decade. Surgical resection with adjuvant systemic chemotherapy …
mortality within the next decade. Surgical resection with adjuvant systemic chemotherapy …
Therapeutic developments in pancreatic cancer: current and future perspectives
The overall 5-year survival for pancreatic cancer has changed little over the past few
decades, and pancreatic cancer is predicted to be the second leading cause of cancer …
decades, and pancreatic cancer is predicted to be the second leading cause of cancer …
[HTML][HTML] Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre …
JP Neoptolemos, DH Palmer, P Ghaneh, EE Psarelli… - The Lancet, 2017 - thelancet.com
Background The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care
based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in …
based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in …
NCCN guidelines insights: pancreatic adenocarcinoma, version 1.2019: featured updates to the NCCN guidelines
MA Tempero, MP Malafa, EG Chiorean, B Czito… - Journal of the National …, 2019 - jnccn.org
The NCCN Guidelines for Pancreatic Adenocarcinoma discuss the diagnosis and
management of adenocarcinomas of the exocrine pancreas and are intended to assist with …
management of adenocarcinomas of the exocrine pancreas and are intended to assist with …
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
T Conroy, P Pfeiffer, V Vilgrain, A Lamarca… - Annals of …, 2023 - annalsofoncology.org
The opportunity to detect pancreatic cancer (PC) when potentially curable depends on early
diagnosis and an ability to identify and screen high-risk populations before symptoms arise …
diagnosis and an ability to identify and screen high-risk populations before symptoms arise …
An update on treatment options for pancreatic adenocarcinoma
Pancreatic cancer is one of the most lethal solid organ tumors. Due to the rising incidence,
late diagnosis, and limited treatment options, it is expected to be the second leading cause …
late diagnosis, and limited treatment options, it is expected to be the second leading cause …